LYEL News & Analysis
2 articles
Market Mood
Lyell Immunopharma (LYEL) Earnings Beat Estimates by $0.22
Lyell Immunopharma (LYEL) reported earnings that surpassed estimates by $0.22. However, the company’s revenue did not meet expectations. The specifics of the revenue shortfall were not detailed in the report. This performance could influence investor sentiment as earnings surprises often impact stock prices, making it relevant for those tracking LYEL.
Read More: Lyell Immunopharma (LYEL) Earnings Beat Estimates by $0.22
Lyell Immunopharma (LYEL) Initiated with Buy Rating and $44 Target
Stifel has initiated coverage of Lyell Immunopharma (LYEL) with a buy rating and a price target of $44. This rating suggests confidence in the stock's potential performance. Initiating coverage can impact market perception and investor interest, potentially leading to increased trading volume. For investors, this rating indicates possible appreciation in stock value for Lyell Immunopharma.
Read More: Lyell Immunopharma (LYEL) Initiated with Buy Rating and $44 Target